Literature DB >> 25992151

Quality of life in swallowing disorders after nonsurgical treatment for head and neck cancer.

Marta Halina Silveira1, Rogerio A Dedivitis2, Débora Santos Queija1, Paulo César Nascimento3.   

Abstract

Introduction Radiotherapy or chemoradiotherapy can result in severe swallowing disorders with potential risk for aspiration and can negatively impact the patient's quality of life (QOL). Objective To assess swallowing-related QOL in patients who underwent radiotherapy/chemoradiotherapy for head and neck cancer. Methods We interviewed 110 patients (85 men and 25 women) who had undergone exclusive radiotherapy (25.5%) or concomitant chemoradiotherapy (74.5%) from 6 to 12 months before the study. The Quality of Life in Swallowing Disorders (SWAL-QOL) questionnaire was employed to evaluate dysphagia-related QOL. Results The QOL was reduced in all domains for all patients. The scores were worse among men. There was a relationship between oral cavity as the primary cancer site and the fatigue domain and also between advanced cancer stage and the impact of food selection, communication, and social function domains. Chemoradiotherapy association, the presence of nasogastric tube and tracheotomy, and the persistence of alcoholism and smoking had also a negative effect on the QOL. Conclusions According to the SWAL-QOL questionnaire, the dysphagia-related impact on QOL was observed 6 to 12 months after the treatment ended.

Entities:  

Keywords:  chemotherapy; deglutition disorders; dysphagia; head and neck neoplasms; quality of life; radiotherapy

Year:  2014        PMID: 25992151      PMCID: PMC4392544          DOI: 10.1055/s-0034-1395790

Source DB:  PubMed          Journal:  Int Arch Otorhinolaryngol        ISSN: 1809-4864


Introduction

Use of radiotherapy with or without chemotherapy as primary treatment for cancer of the head and neck has increased over the past decades. Although the primary goal of treatment is to cure, a perceived additional benefit is the preservation of the organs of the head and neck. Thus, swallowing function after treatment is of major interest.1 However, the current literature indicates that, despite the anatomical preservation of the structures, swallowing function is not maintained at normal levels after treatment.2 3 4 Some alternative feeding route can be necessary due to dysphagia during or after the oncological treatment, which can impair the patient's quality of life (QOL).5 6 7 Although many modalities could demonstrate organic dysfunction in swallowing, the patient's subjective self-perception seems the most significant outcome measure. A questionnaire for measuring a patient's perception of dysphagia and its effect on QOL was developed.5 6 7 This tool, known as the Quality of Life in Swallowing Disorders (SWAL-QOL)8 9 10 questionnaire, is validated, reliable, and reproducible for assessing the perception of dysphagia and has been validated in Brazilian Portuguese.11 Recently, the psychometric and clinical validity of the SWAL-QOL questionnaire was tested in patients with oral and oropharyngeal cancer and was found to be reliable, clinically feasible, and useful for evaluating swallowing problems. A difference of 12 points or more in score was considered clinically and statistically relevant in comparing groups of patients.12 The aim of this study is to evaluate swallowing-related QOL in patients who underwent radiotherapy or chemoradiotherapy for treatment of head and neck tumors.

Methods

This cross-sectional study consisted of 110 previously untreated patients from 21 to 87 years old (median, 61; 77.3% men and 22.7% women) who underwent radiotherapy or concomitant chemoradiotherapy for the treatment of head and neck squamous cell carcinoma. The protocol was approved by the research board, and the patients gave their consent for participation in this study. They were prospectively enrolled in the study from 6 to 12 months after the treatment ended. All patients were evaluated between May and August 2012 at the Service of Radiotherapy of the institution in which treatment was performed. All patients completed the study. Their data are presented in Table 1.
Table 1

Patient characteristics (n = 110)

VariableCategory n (%)
Age (y)Minimum–maximum25th percentile50th percentile (median)75th percentile21–8756.062.069.0
SexFemaleMale25 (22.70)85 (77.30)
Tumor siteOral cavityOropharynxNasopharynxLarynxHypopharynxUnknown primary8 (7.30)33 (30.0)9 (8.20)24 (21.80)10 (9.10)26 (23.60)
TT0T1T2T3T42 (1.80)27 (24.50)24 (21.80)28 (25.50)29 (26.40)
NN0N1N2aN2bN2cN363 (57.30)9 (8.20)16 (14.50)10 (9.10)7 (6.40)5 (4.50)
Treatment modalitiesExclusively conventional radiotherapyChemoradiation28 (25.50)82 (74.50)
Nasogastric tubeNoDuring radiotherapyDuring and after radiotherapyIn use77 (70)9 (8.20)16 (14.50)8 (7.30)
TracheotomyNoDefinitiveDuring radiotherapyUnder temporary use85 (77.30)8 (7.30)13 (11.80)4 (3.60)
Keep smokingNoYes66 (60)44 (40)
Keep drinkingNoYes80 (72.70)30 (27.30)
The patients were asked to fill out the SWAL-QOL questionnaire previously validated in Brazilian Portuguese.11 It is a 44-item tool for assessing swallowing-related WOL, using 11 domains, including burden, desire, eating duration, symptoms frequency, food selection, communication, fear, mental health, sleep, social, and fatigue. Scores were calculated from each SWAL-QOL domain on a scale from 0 to 100, with a score of 100 representing the most favorable state. The questionnaires were filled out once in a cross-sectional analysis by the patient alone or with the help of a relative or an interviewer if the patient was illiterate. Epidemiologic and clinicopathologic details were obtained from the charts. Central trend and variability measurements were used to describe the numerical variables and the frequency distributions for categorical variables. To investigate associations between numerical variables (measurements) in groups with two categories, the nonparametric Mann-Whitney U test was applied; with three or more categories, the nonparametric Kruskal-Wallis test was used. When statistically significant differences were identified, the significance value was adjusted by means of Bonferroni correction. A significance level of 5% was used for all statistical tests, unless adjusted through Bonferroni correction, in which cases new significance values are presented. The IBM-SPSS statistical computer software (IBM-SPSS Statistics GradPack, Armonk, USA), version 21.0, was used to perform the statistical analysis.

Results

The SWAL-QOL questionnaire indicated low median levels, generally with worse scores for desire, mental health, burden, and eating duration domains (Table 2).
Table 2

Quality of life in swallowing disorders (SWAL-QOL)

Variable n min.–max.25th percentile50th percentile75th percentile
Burden1100–1002550100
Desire1100–100164166
Eating duration1100–100252575
Symptom frequency1103.5–100446082
Food selection1100–1002575100
Communication1100–1002575100
Fear1106.2–100377593
Mental health1100–1002060100
Social1100–1003875100
Sleep1100–10050100100
Fatigue1100–1004175100

Abbreviations: max., maximum; min., minimum; SWAL-QOL, Quality of Life in Swallowing Disorders questionnaire.

Abbreviations: max., maximum; min., minimum; SWAL-QOL, Quality of Life in Swallowing Disorders questionnaire. The association between sex and the SWAL-QOL questionnaire was verified and the scores showed higher QOL impact among men in almost all domains, including eating duration (p = 0.003), mental health (p = 0.006), and symptom frequency (p = 0.022). Other domains also presented differences of more than 12 points but lacked statistical significance (desire, communication, fear, and sleep; Table 3).
Table 3

Association between SWAL-QOL and sex

VariableSex n min.–max.25th percentile50th percentile75th percentile p
BurdenFemale250–10050621000.038a
Male850–100255093.75
Total1100–1002550100
DesireFemale2516.60–1002941750.120
Male850–100163366
Total1100–100164166
Eating durationFemale2525–10025501000.003a
Male850–100255050
Total1100–100252575
Symptom frequencyFemale2526.70–1005376830.022a
Male853.50–100395778
Total1103.50–100446082
Food selectionFemale2525–10025751000.287
Male850–1002575100
Total1100–1002575100
CommunicationFemale250–10050751000.204
Male850–1002575100
Total1100–1002575100
FearFemale2525–10046811000.111
Male856.20–100347587
Total1106.20–100377593
Mental healthFemale2510–10055901000.006a
Male850–1001250100
Total1100–1002060100
SocialFemale2525–10070851000.034a
Male850–1003570100
Total1100–1003875100
SleepFemale250–100871001000.051
Male850–10050100100
Total1100–10050100100
FatigueFemale2525–10070831000.043a
Male850–1003375100
Total1100–1004175100

Abbreviations: max., maximum; min., minimum; SWAL-QOL, Quality of Life in Swallowing Disorders questionnaire.

Note: p value according to Mann-Whitney test.

p < 0.05.

Abbreviations: max., maximum; min., minimum; SWAL-QOL, Quality of Life in Swallowing Disorders questionnaire. Note: p value according to Mann-Whitney test. p < 0.05. The primary tumor site was significantly correlated between oral cavity tumors and the fatigue domain (p = 0.041). There was a difference of more than 12 points in the communication domain for the larynx in comparison with other sites, which was not statistically significant. Patients with advanced primary tumors (T4) had the worst results for the food selection (p = 0.037), communication (p = 0.022), and social (p = 0.021) domains. There were more than 12-point differences in scores for the burden, desire, eating duration, and mental health domains, suggesting that those patients had a worse QOL. On the other hand, the association between the regional stage (N) and the SWAL-QOL did not present a statistically significant correlation in the questionnaire domains. A total of 82 of the 110 patients underwent chemotherapy concomitant to the radiotherapy. The result in the burden domain was worse in this group (p = 0.020) than in the group of exclusive radiotherapy. The scores presented a difference for the communication (50 × 25) and fatigue (27.08 × 50) domains but lacked statistical significance. The presence of a nasogastric tube impacted on almost all domains, mainly eating duration (p < 0.001), symptom frequency (p < 0.001), food selection (p < 0.001), mental health (p < 0.001), and social (p < 0.001; Table 4). Bonferroni correction showed differences in the eating duration, frequency of symptoms, food selection, and mental health domains. Furthermore, the use of nasogastric tube during and after radiotherapy also interfered with some QOL aspects (Table 5).
Table 4

Association between SWAL-QOL and the presence of nasogastric tube

VariableNasogastric tube n min.–max.25th percentile50th percentile75th percentile p
BurdenNo770–10025501000.032a
During RT90–10005062
During/after RT1612–100253768
In use80–7502534
Total1100–1002550100
DesireNo770–1002541750.093
During RT90–6684158
During/after RT160–100164150
In use80–7521260
Total1100–10016466
Eating durationNo770–100255081< 0.001a
During RT90–5002537
During/after RT160–100252525
In use80–500018
Total1100–100252575
Symptom frequencyNo777.10–100526685
During RT925–66254653< 0.001a
During/after RT1626.70–83.90385669
In use83.50–71.40102246
Total1103.50–100446082
Food selectionNo770–1002575100< 0.001a
During RT90–100252575
During/after RT1625–100253775
In use80–500043
Total1100–1002575100
CommunicationNo770–10050751000.031a
During RT90–100050100
During/after RT160–100662100
In use80–10001850
Total1100–1002575100
FearNo7712.50–10056811000.001a
During RT918.70–93.70252581
During/after RT1625–100325085
In use86.20–93.70122565
Total1106.20–100377593
Mental healthNo770–1004080100< 0.001a
During RT90–7552560
During/after RT160–100163773
In use80–500723
Total1100–1002060100
SocialNo770–1005785100< 0.001a
During RT935–75354072
During/after RT160–100254782
In use80–3501225
Total1100–1003875100
SleepNo770–100681001000.458
During RT925–1005087100
During/after RT1625–1005093100
In use812.50–1005075100
Total1100–10050100100
FatigueNo770–10062831000.001a
During RT90–100255066
During/after RT160–1003375100
In use80–83.3082562
Total1100–1004175100

Abbreviations: max., maximum; min., minimum; RT, radiotherapy; SWAL-QOL, Quality of Life in Swallowing Disorders questionnaire.

Note: p value according to Kruskal-Wallis test.

p < 0.05.

Table 5

Association between SWAL-QOL and the presence of nasogastric tube

VariableNot during radiotherapyNot during/after radiotherapyNot in useDuring radiotherapy or during/after radiotherapyDuring radiotherapy or in useDuring/after radiotherapy or in use
Burden0.1560.2370.0110.6260.3720.036
Eating duration0.0150.061< 0.001a 0.3050.1380.006a
Symptom frequency 0.003a 0.030< 0.001a 0.0840.0920.009
Food selection0.0210.046< 0.001a 0.3730.0700.006a
Communication0.1390.2530.0070.6380.4550.166
Fear0.0130.1390.0020.2280.3240.059
Mental health0.005a 0.020< 0.001a 0.3920.1550.016
Social0.004a 0.009< 0.001a 0.8860.001a 0.011
Fatigue0.008a 0.3170.001a 0.1440.2410.024

Abbreviations: max., maximum; min., minimum; RT, radiotherapy; SWAL-QOL, Quality of Life in Swallowing Disorders questionnaire.

Note: p value according to Bonferroni correction (p = 0.008512).

Abbreviations: max., maximum; min., minimum; RT, radiotherapy; SWAL-QOL, Quality of Life in Swallowing Disorders questionnaire. Note: p value according to Kruskal-Wallis test. p < 0.05. Abbreviations: max., maximum; min., minimum; RT, radiotherapy; SWAL-QOL, Quality of Life in Swallowing Disorders questionnaire. Note: p value according to Bonferroni correction (p = 0.008512). The questionnaire also identified a statistically significant impact of the definitive tracheotomy in the communication domain (p < 0.001; Tables 6 and 7).
Table 6

Association between SWAL-QOL and the presence of tracheotomy

VariableTracheotomy n min.–max.25th percentile50th percentile75th percentile p
BurdenNo850–10025501000.042a
Definitive80–1000643
Temporary during RT1312.50–100253750
Temporary use40–87.5065084
Total1100–1002550100
DesireNo850–1002041700.133
Definitive80–5081643
Temporary during RT130–100124175
Temporary use40–83.3022472
Total1100–100164166
Eating durationNo850–1002525750.153
Definitive80–7562543
Temporary during RT130–100252537
Temporary use40–10001281
Total1100–100252575
Symptom frequencyNo857.10–100486085
Definitive83.50–912444630.042a
Temporary during RT1326.70–75395060
Temporary use48.90–78.50124675
Total1103.50–100446082
Food selectionNo850–10025751000.019a
Definitive80–75252525
Temporary during RT130–100255087
In temporary use40–75125671
Total1100–1002575100
CommunicationNo850–10050100100< 0.001a
Definitive80–10065050
Temporary during RT130–10002562
Temporary use40–250018
Total1100–1002575100
FearNo8512.50–10046811000.022a
Definitive86.20–93.70253157
Temporary during RT1325–100283787
Temporary use425–100254692
Total1106.20–100377593
Mental healthNo850–10025701000.054
Definitive85–10061525
Temporary during RT1310–100204575
Temporary use40–10003592
Total1100–1002060100
SocialNo850–10040751000.003a
Definitive815–75223253
Temporary during RT130–100154087
Temporary use40–85177282
Total1100–1003875100
SleepNo850–100501001000.207
Definitive850–10050628
Temporary during RT1325–10068100100
Temporary use412.50–1002175100
Total1100–10050100100
FatigueNo850–10058751000.199
Definitive825–100253775
Temporary during RT130–1002983100
Temporary use40–10003793
Total1100–1004175100

Abbreviations: max., maximum; Min., minimum; RT, radiotherapy; SWAL-QOL, Quality of Life in Swallowing Disorders (SWAL-QOL) questionnaire.

Note: p value according to Kruskal-Wallis test.

p < 0.05.

Table 7

Association between SWAL-QOL and the permanence of tracheotomy

VariableNot definitivelyNot temporarily during RTNot in temporary useDefinitively or temporarily during RTDefinitively in temporary useTemporarily during RT in temporary use
Burden0.1150.1160.05250.0510.3320.908
Symptom frequency0.0680.0320.02120.5140.8650.821
Food selection0.005a 0.01900.1990.0910.2750.773
Communication0.0190.002a 0.002a 0.6280.0590.110
Fear0.0090.0680.3460.2390.4810.818
Social0.002a 0.0220.3080.6360.2670.690

Abbreviations: max., maximum; Min., minimum; RT, radiotherapy; SWAL-QOL, Quality of Life in Swallowing Disorders questionnaire.

Note: p value according to Mann-Whitney test adjusted by Bonferroni correction.

p = 0.008512.

Abbreviations: max., maximum; Min., minimum; RT, radiotherapy; SWAL-QOL, Quality of Life in Swallowing Disorders (SWAL-QOL) questionnaire. Note: p value according to Kruskal-Wallis test. p < 0.05. Abbreviations: max., maximum; Min., minimum; RT, radiotherapy; SWAL-QOL, Quality of Life in Swallowing Disorders questionnaire. Note: p value according to Mann-Whitney test adjusted by Bonferroni correction. p = 0.008512. Alcohol consumption had a negative influence on QOL in the domains of communication (p = 0.020) and mental health (p = 0.031). The burden (25 × 9.38), social (40 × 33.75), and fatigue (52 × 33.3) domains were identified via differences in scores as well. On the other hand, patients who continued to smoke presented worse results on the burden (p = 0.003), mental health (p = 0.030), and fatigue (p = 0.028) domains.

Discussion

The incidence of posttreatment dysphagia in patients with head and neck cancer has previously been reported to be between 50 and 60%.13 14 Furthermore, it has been estimated that 30 to 50% of patients with head and neck cancer demonstrate some degree of malnutrition.5 The combination of dysphagia with poor nutrition, significant weight loss, and impaired immune function often results in cachexia, fatigue, high susceptibility to infection, poor wound healing, or death.5 15 The most common acute side effects of chemoradiotherapy are mucositis, pain, dermatitis, xerostomia, loss of taste, hoarseness, weight loss, myelosuppression, nausea, and dysphagia. The most frequent late side effects are xerostomia, loss of taste, fibrosis, trismus, and dysphagia. Dysphagia has a potential for aspiration and death due to aspiration pneumonia.5 16 Thus, it is important to evaluate the short-, medium-, and long-term functional outcomes of radiotherapy treatment associated or not with chemotherapy. Some factors related to pretreatment status, such as weight, staging, primary tumor site, and treatment modality, interfere in the outcome and the QOL.17 18 19 We found the median scores of SWAL-QOL for the whole group showed some loss in almost all domains, even 6 to 12 months following treatment completion. Some aspects specifically related to feeding, such as desire, eating duration, burden, food selection, and fear, seemed to have relevance for those patients, jeopardizing their mental health. A person with dysphagia spends a longer time eating, presents lower skill to eat varied food, and can be afraid, constrained, and/or incapable of eating in public, remaining socially isolated and depressed.14 Men are more prone to be affected than women, showing a greater difficulty to adapt. Dysphagia is common after the treatment of head and neck cancer; mucositis, nausea, loss of eating desire, taste changing, and xerostomia can make eating difficult and cause fatigue, jeopardizing the QOL.20 The fatigue domain presented a higher impact among patients with oral cancer. In fact, eating for a longer time can cause a feeling of fatigue. On the other hand, laryngeal cancer showed an impact on communication, due to mucosa dryness, fibrosis, muscular atrophy, and edema, which are consequent to radiotherapy and can affect vocal production.21 22 23 In addition, tumor location itself has some importance. Patients with advanced primary tumor presented worse results. In contrast, the stratification of the patients according to the cervical staging (N) had no relationship with the QOL in our study, but other studies found that bilateral neck irradiation contributes to worse functional outcome.18 Most of our patients (74.5%) underwent concomitant chemoradiotherapy with greater harm on the burden domain. The effects of late radiation-induced toxicity on deglutition and the salivary glands are more intense in the first 12 months after treatment and decrease gradually after 18 to 24 months.24 It should also be mentioned that dysphagia and QOL are damaged in advanced tumors, worsen during chemoradiotherapy, and improve 6 months after the treatment.25 We studied patients whose period after the treatment conclusion varied from 6 to 12 months. When the SWAL-QOL was associated with the type of treatment, the first aspect accentuated was the domain of burden (which is related to dysphagia), followed by the domains of fatigue (related to feeding deficit) and communication (related to the tumor and treatment sequel). The use of a nasogastric tube had an important impact on all domains of the questionnaire, worsening the QOL. A nasogastric tube changes the daily routine and needs special care. Furthermore, feeding time is longer than habitual, and as a result there are social isolation and mental health aspects to its use. The weight loss during and in the 3 months after radiotherapy is independently associated with the QOL in patients with head and neck cancer.26 The use of tracheotomy also affects the QOL, according to the questionnaire, mainly with regard to communication, mental health, and social life. These three domains are clearly related to each other in patients with tracheotomy. The communication domain showed a higher impact during temporary use and during the radiotherapy performance, whereas the social function and food selection domains more often identified definitive use. Food selection harm can be a consequence of posttreatment edema, which damages the pharyngeal transit and might require dietary adaptation to minimize the treatment sequela.23 Mental health was jeopardized among patients who continued to consume tobacco and alcohol. Such patients are prone to depression. The maintenance of those habits is responsible for a lower QOL.17 18 27 28 Dysphagia is generally underdiagnosed or is not properly considered. Despite not replacing the clinical and instrumental evaluations, QOL questionnaires can contribute to evaluating specific aspects regarding the patient's well-being and can point out some characteristics that are not measured by pathophysiological parameters.29 30

Conclusion

The effects of radiotherapy and chemoradiotherapy on swallowing function are relevant on dysphagia-related QOL. The harm caused by dysphagia from 6 to 12 months after treatment is recognized by patients with advanced tumors. The type of treatment (concomitant combined radiotherapy and chemotherapy), use of nasogastric tube, tracheotomy, and continuation of tobacco and alcohol habits contribute to decreased QOL. The SWAL-QOL questionnaire is a useful and sensible tool to detect difficulties and perspectives of patients with head and neck cancer.
  29 in total

1.  The SWAL-QOL outcomes tool for oropharyngeal dysphagia in adults: II. Item reduction and preliminary scaling.

Authors:  C A McHorney; D E Bricker; J Robbins; A E Kramer; J C Rosenbek; K A Chignell
Journal:  Dysphagia       Date:  2000       Impact factor: 3.438

2.  Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy.

Authors:  Kent W Mouw; Abhishek A Solanki; Kerstin M Stenson; Mary Ellyn Witt; Elizabeth A Blair; Ezra E W Cohen; Everett E Vokes; Marcy List; Daniel J Haraf; Joseph K Salama
Journal:  Oral Oncol       Date:  2012-05-22       Impact factor: 5.337

3.  The SWAL-QOL and SWAL-CARE outcomes tool for oropharyngeal dysphagia in adults: III. Documentation of reliability and validity.

Authors:  Colleen A McHorney; Joanne Robbins; Kevin Lomax; John C Rosenbek; Kimberly Chignell; Amy E Kramer; D Earl Bricker
Journal:  Dysphagia       Date:  2002       Impact factor: 3.438

4.  Clinical validity of the SWAL-QOL and SWAL-CARE outcome tools with respect to bolus flow measures.

Authors:  Colleen A McHorney; Bonnie Martin-Harris; JoAnne Robbins; John Rosenbek
Journal:  Dysphagia       Date:  2006-07       Impact factor: 3.438

5.  Impact of dysphagia on quality of life after treatment of head-and-neck cancer.

Authors:  Nam P Nguyen; Cheryl Frank; Candace C Moltz; Paul Vos; Herbert J Smith; Ulf Karlsson; Suresh Dutta; Allan Midyett; Jessica Barloon; Sabah Sallah
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-03-01       Impact factor: 7.038

6.  Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy.

Authors:  Johannes A Langendijk; Patricia Doornaert; Irma M Verdonck-de Leeuw; Charles R Leemans; Neil K Aaronson; Ben J Slotman
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

Review 7.  Dysphagia in head and neck cancer patients treated with chemoradiotherapy.

Authors:  Nele Platteaux; Piet Dirix; Eddy Dejaeger; Sandra Nuyts
Journal:  Dysphagia       Date:  2009-08-27       Impact factor: 3.438

8.  Impact of adding concomitant chemotherapy to hyperfractionated accelerated radiotherapy for advanced head-and-neck squamous cell carcinoma.

Authors:  Sandra Nuyts; Piet Dirix; Paul M J Clement; Vincent Vander Poorten; Pierre Delaere; Joseph Schoenaers; Robert Hermans; Walter Van den Bogaert
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-08-15       Impact factor: 7.038

Review 9.  Dysphagia following chemoradiation for locally advanced head and neck cancer.

Authors:  N P Nguyen; C C Moltz; C Frank; P Vos; H J Smith; U Karlsson; S Dutta; F A Midyett; J Barloon; S Sallah
Journal:  Ann Oncol       Date:  2004-03       Impact factor: 32.976

10.  More than 10% weight loss in head and neck cancer patients during radiotherapy is independently associated with deterioration in quality of life.

Authors:  Jacqueline A E Langius; Anne M van Dijk; Patricia Doornaert; Hinke M Kruizenga; Johannes A Langendijk; C René Leemans; Peter J M Weijs; Irma M Verdonck-de Leeuw
Journal:  Nutr Cancer       Date:  2013       Impact factor: 2.900

View more
  6 in total

1.  The course of swallowing problems in the first 2 years after diagnosis of head and neck cancer.

Authors:  Jorine A Vermaire; Cornelis P J Raaijmakers; Evelyn M Monninkhof; C René Leemans; Robert J Baatenburg de Jong; Robert P Takes; Irma M Verdonck-de Leeuw; Femke Jansen; Johannes A Langendijk; Chris H J Terhaard; Caroline M Speksnijder
Journal:  Support Care Cancer       Date:  2022-08-30       Impact factor: 3.359

2.  Recommendation of Nasogastric Tube Removal in Acute Stroke Patients Based on Videofluoroscopic Swallow Study.

Authors:  Jong-Moon Hwang; Youn-Soo Cheong; Min-Gu Kang; Seong Min Chun; Yu-Sun Min; Yang-Soo Lee; Tae-Du Jung
Journal:  Ann Rehabil Med       Date:  2017-02-28

3.  Swallowing, nutritional status, and salivary flow in patients after head and neck cancer treatment, a pilot study.

Authors:  Mariana Inri de Carvalho; Marina Gatti; Renata Ligia Vieira Guedes; Renata Camilla Favarin Froes; Danila Rodrigues Costa; Jhonatan da Silva Vitor; Paulo Sérgio da Silva Santos; Giédre Berretin-Felix
Journal:  Sci Rep       Date:  2021-10-12       Impact factor: 4.379

Review 4.  Impact of Tobacco Smoking on Outcomes of Radiotherapy: A Narrative Review.

Authors:  Adrian Perdyan; Jacek Jassem
Journal:  Curr Oncol       Date:  2022-03-24       Impact factor: 3.109

Review 5.  Assessment of cough in head and neck cancer patients at risk for dysphagia-An overview.

Authors:  Sofiana Mootassim-Billah; Gwen Van Nuffelen; Jean Schoentgen; Marc De Bodt; Tatiana Dragan; Antoine Digonnet; Nicolas Roper; Dirk Van Gestel
Journal:  Cancer Rep (Hoboken)       Date:  2021-05-01

6.  Psychometric Properties of the MDADI-A Preliminary Study of Whether Less is Truly More?

Authors:  Daniel J Lin; Jenan Altamimi; Kim Pearce; Janet A Wilson; Joanne M Patterson
Journal:  Dysphagia       Date:  2021-03-11       Impact factor: 3.438

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.